Susquehanna Fundamental Investments LLC Acquires New Stake in Illumina, Inc. (NASDAQ:ILMN)

Susquehanna Fundamental Investments LLC purchased a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 84,570 shares of the life sciences company's stock, valued at approximately $11,301,000. Susquehanna Fundamental Investments LLC owned approximately 0.05% of Illumina at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of ILMN. Wilmington Savings Fund Society FSB acquired a new stake in Illumina during the 3rd quarter valued at $772,000. Tidal Investments LLC boosted its stake in shares of Illumina by 38.0% during the third quarter. Tidal Investments LLC now owns 4,449 shares of the life sciences company's stock valued at $580,000 after acquiring an additional 1,226 shares during the last quarter. B. Riley Wealth Advisors Inc. lifted its position in shares of Illumina by 66.8% during the third quarter. B. Riley Wealth Advisors Inc. now owns 11,973 shares of the life sciences company's stock worth $1,582,000 after purchasing an additional 4,797 shares in the last quarter. Versant Capital Management Inc increased its stake in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after buying an additional 146 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in Illumina by 6.1% in the 4th quarter. GAMMA Investing LLC now owns 3,096 shares of the life sciences company's stock worth $414,000 after buying an additional 177 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.

Analysts Set New Price Targets

ILMN has been the topic of a number of analyst reports. Guggenheim dropped their target price on Illumina from $170.00 to $150.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. Morgan Stanley cut their target price on Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a research report on Tuesday, February 11th. Barclays decreased their price target on shares of Illumina from $100.00 to $77.00 and set an "underweight" rating for the company in a research report on Thursday, April 10th. TD Cowen cut shares of Illumina from a "buy" rating to a "hold" rating and cut their price target for the company from $177.00 to $140.00 in a report on Friday, February 7th. Finally, Canaccord Genuity Group decreased their price objective on shares of Illumina from $115.00 to $92.00 and set a "hold" rating for the company in a report on Tuesday. One analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $137.55.

Illumina Stock Performance

NASDAQ ILMN traded up $1.39 during trading hours on Friday, hitting $77.90. The company had a trading volume of 614,247 shares, compared to its average volume of 2,278,861. The business has a fifty day simple moving average of $80.43 and a 200-day simple moving average of $116.34. The firm has a market cap of $12.33 billion, a P/E ratio of -10.11, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Equities analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.